
Quarterly report 2024-Q4
added 01-10-2025
Accolade Financial Statements 2011-2026 | ACCD
Annual Financial Statements Accolade
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
764 M | - | - | - | - | - | - | - | - | - | - |
Shares |
29.4 M | - | - | - | - | - | - | - | - | - | - |
Historical Prices |
26.4 | 43.5 | - | - | - | - | - | - | - | - | - |
Net Income |
-50.7 M | -51.4 M | -56.5 M | -61.3 M | - | - | - | - | - | - | - |
Revenue |
170 M | 133 M | 94.8 M | 76.8 M | - | - | - | - | - | - | - |
Cost of Revenue |
93.7 M | 73.7 M | 60.6 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | 58.8 M | 34.2 M | 23.4 M | - | - | - | - | - | - | - |
Operating Income |
-46.8 M | -48.2 M | -54 M | - | - | - | - | - | - | - | - |
Interest Expense |
-147 K | -107 K | -90 K | - | - | - | - | - | - | - | - |
EBITDA |
-38.6 M | -39.7 M | -44.6 M | -51.5 M | - | - | - | - | - | - | - |
Operating Expenses |
123 M | 107 M | 88.2 M | 82.9 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
31.6 M | 26.2 M | 19.7 M | 21.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Accolade
| 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
80.6 M | 80.1 M | 78.1 M | 78.1 M | 76.1 M | 75.5 M | 73.2 M | 73.1 M | 71.2 M | 70.5 M | 69.7 M | 67.1 M | 65.4 M | 62.7 M | 61.3 M | 55.7 M | 51.6 M | 30.6 M | 33 M | 7.52 M | 5.78 M | 5.34 M | 4.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-121 M | -23.9 M | -27.6 M | - | -21.1 M | -32.8 M | -38.4 M | - | -39.9 M | -46.5 M | -343 M | - | 22.5 M | -88.6 M | -48.7 M | -48.7 M | -16.6 M | -16.6 M | -15.4 M | -14 M | -18.3 M | -15 M | -15.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
105 M | 106 M | 110 M | - | 99.4 M | 96.9 M | 93.2 M | - | 90.9 M | 87.6 M | 85.5 M | - | 83.4 M | 216 M | 133 M | 59.5 M | 38.4 M | 38.4 M | 36.8 M | 35.9 M | 29.7 M | 29.7 M | 28.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
58.6 M | 56.9 M | 58.6 M | - | 54.5 M | 55.3 M | 54.2 M | - | 50.4 M | 49.8 M | 47.6 M | - | 45.2 M | 125 M | 80.3 M | 35.9 M | 22.7 M | 22.7 M | 21.1 M | 22.2 M | 17.5 M | 16.8 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-122 M | -25.1 M | -29 M | - | -31.7 M | -35.2 M | -39.6 M | - | -40.4 M | -45.9 M | -346 M | - | 26.5 M | -95.9 M | -122 M | -48 M | -16.5 M | -16.5 M | -12.9 M | -12.6 M | -17.4 M | -14.3 M | -15.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-69 K | -103 K | 94 K | - | 9.28 M | 753 K | 390 K | - | 201 K | -130 K | -50 K | - | 25 K | -19 K | -44 K | -55 K | -42 K | -42 K | -104 K | -15 K | -18 K | -46 K | -34 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-112 M | -14.5 M | -18.7 M | - | -20.3 M | -24.4 M | -28 M | - | -28.8 M | -34.3 M | -334 M | - | 37.8 M | -64.9 M | -103 M | -39.3 M | -14.4 M | -10.4 M | -8.92 M | -10.7 M | -15.4 M | -12 M | -13.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
169 M | 74.6 M | 80.9 M | - | 76.6 M | 76.8 M | 78.7 M | - | 80.9 M | 83.7 M | 384 M | - | 11.7 M | 187 M | 175 M | 71.6 M | 32.2 M | 32.2 M | 28.6 M | 26.3 M | 29.6 M | 27.2 M | 26.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
16.2 M | 16.5 M | 16 M | - | 15.5 M | 16.3 M | 16.1 M | - | 20 M | 21 M | 20.2 M | - | 21.5 M | 69.6 M | 48.2 M | 22 M | 8.41 M | 8.41 M | 6.45 M | 5.67 M | 8.55 M | 6.01 M | 5.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Accolade ACCDFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Accolade plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Health Catalyst
HCAT
|
$ 1.1 | -9.5 % | $ 76.9 M | ||
|
American Well Corporation
AMWL
|
$ 5.76 | -0.52 % | $ 92.4 M | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
HealthStream
HSTM
|
$ 20.97 | -0.76 % | $ 637 M | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
Omnicell
OMCL
|
$ 34.46 | 0.44 % | $ 1.59 B | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
OptimizeRx Corporation
OPRX
|
$ 6.78 | 5.44 % | $ 116 M | ||
|
HealthEquity
HQY
|
$ 82.1 | 0.56 % | $ 7.07 B | ||
|
Phreesia
PHR
|
$ 11.28 | -4.41 % | $ 615 M | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
Evolent Health
EVH
|
$ 2.25 | -9.64 % | $ 211 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
GoodRx Holdings
GDRX
|
$ 2.04 | -1.92 % | $ 787 M | ||
|
Schrödinger
SDGR
|
$ 11.57 | -2.53 % | $ 850 M | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
Teladoc Health
TDOC
|
$ 5.42 | -1.09 % | $ 955 M | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
Zhongchao
ZCMD
|
$ 1.81 | -4.23 % | $ 9.42 M | ||
|
10x Genomics
TXG
|
$ 19.81 | 3.5 % | $ 2.32 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
SCWorx Corp.
WORX
|
$ 0.13 | -4.16 % | $ 190 K | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Progyny
PGNY
|
$ 18.05 | 0.22 % | $ 1.55 B | ||
|
So-Young International
SY
|
$ 2.91 | - | $ 231 M | ||
|
Veeva Systems
VEEV
|
$ 179.11 | -3.3 % | $ 29.3 B |